Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Nervous system disorders – page 53

  • 1 397 clinical trials
  • 586 recruiting
  • 459 conditions
  • 29 countries

Conditions in this area

459 conditions with trials, the busiest first

Dementia Alzheimer's type87Multiple sclerosis59Parkinson's disease56Ischaemic stroke52Migraine48Myasthenia gravis44Glioblastoma41Amyotrophic lateral sclerosis31Duchenne muscular dystrophy28Neuroblastoma26Relapsing multiple sclerosis21Glioma20Relapsing-remitting multiple sclerosis20Narcolepsy19Partial seizures19Cognitive disorder18Epilepsy18Giant cell arteritis18Anaesthesia17Chronic inflammatory demyelinating polyradiculoneuropathy17Spinal muscular atrophy17Subarachnoid haemorrhage16Autism spectrum disorder15Insomnia15+435

Clinical trials in Nervous system disorders

1 397 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 397 clinical trials

Neuroblastoma

Not yet recruiting

Feasibility Study of AloCelyvir and Autologous Tumor‑Infiltrating T Lymphocytes in Children and Young Adults with High‑Risk Relapsed/Refractory Neuroblastoma

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years
  • Substances:Allogenic Bone Marrow-Derived Mesenchymal Stem Cells Transduced With Icovir-5, Ex Vivo Expanded
  • Sponsor:Fundacion Para La Investigacion Biomedica Del Hospital Universitario La Princesa

Epilepsy

Not yet recruiting

Long‑Term Safety and Tolerability of Probenecid (PTI5803) as Adjunctive Therapy in Patients ≥14 Years with Drug‑Resistant Focal Epilepsy due to Focal Cortical Dysplasia

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Probenecid
  • Sponsor:Panntherapi

Neuromyelitis optica spectrum disorder+1

Not yet recruiting

Two dosing schedules of the herpes zoster vaccine (recombinant varicella zoster virus glycoprotein E) in MS and NMOSD patients on rituximab or ocrelizumab

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Ocrelizumab
  • Sponsor:Centre Hospitalier Universitaire De Toulouse

Parkinson's disease

Not yet recruiting

Effect of botulinum toxin type A - haemagglutinin complex on refractory upper‑limb resting tremor in Parkinson disease patients (drug‑combination study)

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Nitrous Oxide
  • Sponsor:Centre Hospitalier Universitaire De Toulouse

Spinal muscular atrophy

Not yet recruiting

Study of BIIB115 in patients aged 15‑60 years with spinal muscular atrophy who are treatment‑naïve or previously treated with risdiplam

InvestigationalNo placebo
Countries:FinlandFinland
  • Participants:0–17 years · 18–64 years
  • Substances:BIIB115
  • Sponsor:Biogen Idec Research Limited

Huntington's disease

Not yet recruiting

Phase 2/3 Randomized Study of SKY-0515 for Safety and Efficacy in Adults with Huntington’s Disease

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years

Disease risk factor+1

Not yet recruiting

Colchicine for Reducing Dependency and Vascular Events in Patients After Acute Intracerebral Hemorrhage

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Colchicine
  • Sponsor:Hamilton Health Sciences Corporation

Epilepsy

Not yet recruiting

Safety and Tolerability of PTI5803 in Patients Aged 14 Years and Older With Drug‑Resistant Seizures Due to Focal Cortical Dysplasia

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Probenecid
  • Sponsor:Panntherapi

Hereditary spastic paraplegia

Not yet recruiting

Study of melpida with drug combination in patients with Hereditary Spastic Paraplegia Type 50 (SPG50)

Registered drugNo placebo
Countries:SpainSpain
  • Participants:0–17 years
  • Substances:Codeine Phosphate

Central nervous system neoplasm

Not yet recruiting

Safety of autologous NK cells with IL‑15 and CD45RA‑negative T cells with NKG2D CAR in children, adolescents and young adults with high‑grade brain tumors

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years
  • Sponsor:Hospital Universitario La Paz

Ischaemic stroke

Not yet recruiting

Phase 2 Study of RADAMTS13 in Adults with Acute Ischemic Stroke

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Sponsor:Takeda Development Center Americas Inc.

Cluster headache

Not yet recruiting

Sodium Oxybate for Nocturnal Cluster Headache Attacks in Adults with Chronic Cluster Headache: A Phase 2 Randomized, Double‑Blind, Placebo‑Controlled Study

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Oxybate
  • Sponsor:Leiden University Medical Center

Substances studied in this area

The therapies tested most often in Nervous system disorders trials.

Sodium Chloride71 clinical trialsTemozolomide38 clinical trialsOcrelizumab33 clinical trialsRituximab27 clinical trialsCyclophosphamide24 clinical trialsParacetamol24 clinical trialsMethylprednisolone15 clinical trialsPrednisolone15 clinical trialsCarboplatin14 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.